Diasorin is engaged in the market for in vitro diagnostics. Co. is developing, producing and commercializing diagnostic tests that are designed for hospital and private testing laboratories for use in different clinical areas in the market of immunodiagnostics and molecular diagnostics. In the immunodiagnostics market segment, Co. develops, produces and markets immunoreagent kits based on three different detection techniques. In the molecular diagnostics segment, Co. supplies end laboratories with an automated solution to perform the three steps required for the final diagnostic result.
  • TickerDIA
  • ISINIT0003492391
  • SectorHealth Care Equipment & Services
  • CountryItaly
Jamila El Bougrini ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - DIASORIN : Des leviers en suspens - NEUTRE, OC 151€ (vs 149€)

Diasorin S.P.A: 1 director bought

A director at Diasorin S.P.A bought 1,500 shares at 155.956EUR and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Un T2 explosif mais un marché très exigeant - NEUTRE (vs VENTE), OC 149€ (vs 131€)

DIASORIN sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of DIASORIN (IT), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date July 28, 2020, the closing price was EUR 170.60 and its target price was estimated at EUR 138.45.

Expert Corporate Governance Service (ECGS)

DiaSorin – AGM 10 june 2020

The following concerns arise over DiaSorin's remuneration policy:   - the vesting of stock options does not depend on any performance conditions, does not depend on any performance conditions,   - both the annual and long-term cash incentives depend on only one absolute performance indicator (EBIT),   - early vesting of incentives and the CEO's indemnity in the event of a change in control (equal to 3 years of cash remuneration) are contrary to our guidelines,   - discretionary bonuses are allowed and no clawback mechanisms are provided.   Therefore, we recommend shareholders to oppo...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care Hitting On All Cylinders Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout... see chart below. • Market Ignoring Negative Headlines. Global equity markets continue to generally shrug off seemingly bearish headlines surrounding trade, Trump impeachment hearings, and ongoing protests in Hong Kong. This tells us that the good outweighs the bad in the eyes of the market. While we view the fact that none of these issues have yet to derail global...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Another test of support Heightened trade tensions have caused global equities to move from resistance to support in a matter of days. Additional consolidation - i.e., no breakdowns - on the broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) remains the most likely scenario. At the same time, new cracks are beginning to show and as a result we believe global equities are vulnerable to a breakdown. • New cracks emerging. Breakdowns in crude oil and new lows for the STOXX 600 Bank supersector are two recent developments which have dampened our overall outlook... see charts below. •...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (R...

Diasorin S.P.A: 1 director bought

A director at Diasorin S.P.A bought 1,500 shares at 155.956EUR and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Jamila El Bougrini ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - DIASORIN : Des leviers en suspens - NEUTRE, OC 151€ (vs 149€)

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Un T2 explosif mais un marché très exigeant - NEUTRE (vs VENTE), OC 149€ (vs 131€)

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Etude sectorielle Medtech : Détecter les faux positifs

MarketLine Department

Bio-Rad Laboratories, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Bio-Rad Laboratories, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bio-Rad Laboratories, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competit...

Martial Descoutures

Publication décevante, prudence à MT - NEUTRE - OC 72€

La réaction du cours hier (-7,2%) fait suite à la publication de résultats décevants, malgré l’impact d’éléments exceptionnels sur le T3 (ouragan, décalages de commandes, charge exceptionnelle de 2m€). Les prises de profits découlent principalement de l’annonce d’un plan de restructuration de 8m€ étalé sur le T4 17 et 2018 visant à fermer l’usine de Dublin pour rassembler les activités en Californie. Les niveaux de valorisation historiquement élevés (PE 17 de 34x) laissent peu de place au doute. Après différents ajustements sur les prévisions et intégration du ...

DIASORIN sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of DIASORIN (IT), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date July 28, 2020, the closing price was EUR 170.60 and its target price was estimated at EUR 138.45.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

Expert Corporate Governance Service (ECGS)

DiaSorin – AGM 10 june 2020

The following concerns arise over DiaSorin's remuneration policy:   - the vesting of stock options does not depend on any performance conditions, does not depend on any performance conditions,   - both the annual and long-term cash incentives depend on only one absolute performance indicator (EBIT),   - early vesting of incentives and the CEO's indemnity in the event of a change in control (equal to 3 years of cash remuneration) are contrary to our guidelines,   - discretionary bonuses are allowed and no clawback mechanisms are provided.   Therefore, we recommend shareholders to oppo...

Expert Corporate Governance Service (ECGS)

DiaSorin - AGM 24 April 2019

In item 2, shareholders are called to an advisory vote on the remuneration policy for executive Directors and other executives with strategic responsibilities. We strongly regret that both the annual and long-term cash incentives depend on only one performance metric (EBIT), meaning that executives are paid twice for achieving the same target. Furthermore, the executive variable remuneration also comprises a stock option plan not depending on any performance conditions. Therefore, we recommend opposition. In item 5, we also recommend opposing the 2019 Stock Option Plan. In item 3.3, the AGM i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch